A carregar...
Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab
This data analysis simulates the annual price of evolocumab under the outcome-based contracts proposed by Amgen and puts estimates in the context of the available evidence on the cost-effectiveness of PCSK9 inhibitors.
Na minha lista:
| Publicado no: | JAMA Intern Med |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5818836/ https://ncbi.nlm.nih.gov/pubmed/28783812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2017.3143 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|